Matthew W. Reynolds
Matt has 16 years of pharmaceutical research experience (13 of those at Evidera) and oversees epidemiology, database, and safety projects, and acts as a principal investigator or advisor on many safety-related and pharmacoepidemiology-based projects such as individual patient database analyses, systematic literature reviews and meta-analysis, customized pharmacoepidemiology and drug safety support, prospective epidemiology studies, and risk management and drug safety consulting. He is the founder of the Database Special Interest Group for the International Society of Pharmacoepidemiology.
Prior to his current role, Matt was the senior director of risk management and safety services at MetaWorks Inc., which was acquired by Evidera in January 2006. His industry expertise is critical in defining research questions and drafting study protocols, directing analyses, and delivering project findings. He has held prior positions with AstraZeneca as associate director of cardiovascular epidemiology; Pharmacia Corporation (formerly Searle Pharmaceutical) as a pharmacoepidemiologist and senior analyst; and, numerous assignments for the School of Medicine at the University of Maryland (Baltimore). As a pharmaco-epidemiologist at Pharmacia and AstraZeneca, Matt designed protocols for a variety of epidemiology studies that spanned the spectrum of diseases in patient populations, their risk factors, and the effectiveness and safety of those treatments. He has published multiple papers in the areas of cardiology, hematology, and infectious disease, and has conducted over 100 scientific presentations and workshops on study results and on various epidemiological methods over the past 15 years.
Matt earned his graduate and doctoral degrees in epidemiology and preventive medicine from the University of Maryland at Baltimore.